News & Insights

Archimedes 2024 Biosimilar Fill Rate Tracker

January 2024

As part of our BiosimilarsFirst program, Archimedes will be sharing our success in driving biosimilar adoption for Humira, Remicade, and across specialty drugs for autoimmune conditions.  Be sure to check back as we update our results.

Plan paid per claim for Low WAC Biosimilars based on 40 MG/0.4ML. quantity of 0.8 for Hadlima. Infliximab plan paid per claim based on 100MG, quantity of 6.

Humira Biosimilar Fill Rate represents low WAC Biosimilars divided by Humira and Humira Biosimilar claims.

Specialty drugs for Autoimmune diseases include Abrilada, Actemra, Adalimumab-aacf, Adalimumab-adaz, Adalimumab-adbm, Adalimumab-fkjp, Amjevita, Avsola, Bimzelx, Cimzia, Cosentyx, Cyltezo, Enbrel, Entyvio, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Ilumya, Inflectra, inFLIXimab, Kevzara, Kineret, Olumiant, Omvoh, Orencia, Otezla, Remicade, Renflexis, Rinvoq, Siliq, Simponi, Simponi Aria, Skyrizi, Sotyktu, Stelara, Taltz, Tremfya, Xeljanz, Yuflyma, and Yusimry.

Infliximab is categorized as a biosimilar for this purpose.

Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now